HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS
Clinical trials for HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS explained in plain language.
Never miss a new study
Get alerted when new HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS trials appear
Sign up with your email to follow new studies for HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo could slash kidney transplant wait times for Hard-to-Match patients
Disease control OngoingThis study tests whether two drugs, daratumumab and belatacept, can lower immune sensitivity in kidney transplant candidates who are highly sensitized, meaning their bodies reject most donor kidneys. Nineteen participants with very high antibody levels receive the drugs to see if…
Matched conditions: HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New drug combo could slash Years-Long wait for kidney transplants
Disease control OngoingThis study tests whether two drugs, carfilzomib and belatacept, can lower the immune sensitivity of kidney transplant candidates who are highly sensitized—meaning their bodies reject most donor kidneys. The goal is to make it easier and quicker to find a compatible donor. About 2…
Matched conditions: HIGHLY SENSITIZED PROSPECTIVE KIDNEY TRANSPLANT RECIPIENTS
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC